Apalutamide with androgen deprivation therapy for treating prostate cancer
Closed for comments This consultation ended on at Request commenting lead permission
2 Information about apalutamide
Marketing authorisation indication
2.1 Apalutamide (Erleada, Janssen) is indicated:
'in adult men for the treatment of non-metastatic castration-resistant prostate cancer in adults who are at high risk of developing metastatic disease
in adult men for the treatment of metastatic hormone-sensitive prostate cancer in combination with androgen deprivation therapy'.
Dosage in the marketing authorisation
2.2 The dosage schedule is available in the summary of product characteristics.
Price
2.3 The price for apalutamide is £2,735 per pack of 112 tablets, each containing 60 mg of the active ingredient (excluding VAT; BNF online, March 2021). The company has a commercial arrangement, which would have applied if the technology had been recommended.
How are you taking part in this consultation?
You will not be able to change how you comment later.
You must be signed in to answer questions